Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.51 |
| ▸ | CNR2 | P34972 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.41 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.41 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371083 | 0.88 | CNR1 (0.50) | CNR1CNR2NPSR1 | |
| SCHEMBL5371206 | 0.86 | CNR2 (0.53) | CNR1CNR2GAAMEN1KMT2A | |
| SCHEMBL5358466 | 0.79 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL5368461 | 0.78 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL10057707 | 0.78 | NPSR1 (0.64) | CNR1CNR2ALDH1A1NPSR1 | |
| SCHEMBL5370544 | 0.78 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5370602 | 0.76 | CNR2 (0.58) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL5375151 | 0.76 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5370352 | 0.76 | CNR1 (0.57) | CNR1CNR2 | |
| SCHEMBL5374690 | 0.73 | CNR2 (0.54) | CNR1CNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER, INC. | 2007-11-01 | — | — | US | claimed |
| JP-2007502808-A | — | — | 2007-02-15 | — | — | JP | claimed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| JP-2006514942-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1626738-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1624895-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| EP-1572662-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2005018645-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043327-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| WO-2004098641-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098580-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040224962-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| WO-2004052864-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-06-24 | — | — | US | claimed |
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER, INC. | 2007-11-01 | — | — | US | disclosed |
| US-7247628-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | disclosed |
| WO-2004052864-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122074-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885GAA 2736/4885 |
| US-20070254935-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885GAA 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.